Assessing the Impact of eSight Go At-Home Usage in Individuals With Visual Impairment (NCT07149259) | Clinical Trial Compass
RecruitingNot Applicable
Assessing the Impact of eSight Go At-Home Usage in Individuals With Visual Impairment
United States50 participantsStarted 2025-06-18
Plain-language summary
This research aims to test the updated version of Gentex's device, eSight Go, an image enhancing wearable device to assist those with vision impairments limiting activities of daily living.
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 18 to 90.
* Best-corrected visual acuity between 20/50 to 20/400 in the better eye.
* Subjects who have been diagnosed with an ocular condition causing visual impairment
* Have a functional binocular field of view of at least 20 degrees.
* Visual status stable for at least six months.
* Demonstrate visual benefit from magnification.
* Agree to wear the eSight Go in a variety of situations in the home and community.
* Score ≥ 20 on the Short Orientation-Memory-Concentration Test of Cognitive Impairment (OMCT).
* Subject must be able to provide an informed consent
* Subject must agree to use eSight Eyewear only under conditions that will not jeopardize the safety of either the user or the device.
Exclusion Criteria:
* Participant must not be currently undergoing any medical or surgical procedures resulting in unstable vision.
* Participants who have undergone cataract, refractive, or other surgical procedures related to vision in the six-month period prior to study enrollment.
* Severe (\>20/400) visual impairment in the better seeing eye.
* Cognitive limitations (\< 20 on OMCT).
* Participants who have undergone any vision-related injections (e.g. anti-VEGF) in the two-month period prior to the study because of active bleeding in the retina. Ongoing anti-VEGF treatments are permitted if the participant is in a "Treat and Extend" or pro re nata ("PRN") disease management, and macula is dry.
* Participants are unable or unwilling to adhere to the ex…
What they're measuring
1
Change in Visual Acuity
Timeframe: Pre-intervention and post-intervention at 4 weeks
2
Change in Reading Performance
Timeframe: Pre-intervention and post-intervention at 4 weeks